DEVELOPMENT
DEVELOPMENT
TissueGen is advancing toward clinical development a pipeline of novel, extended release
TissueGen is advancing toward clinical development a pipeline of novel, extended release
formulations of generic drugs for the treatment of eye, nerve, and joint injuries and diseases.
formulations of generic drugs for the treatment of eye, nerve, and joint injuries and diseases.
WHO WE ARE
TissueGen® is committed to developing next-generation technologies for advanced drug delivery, nerve regeneration and tissue engineering. If you would like to join our team, we would like hear from you. Please contact info@tissuegen.com
MISSION
TissueGen® is committed to developing next-generation technologies for advanced drug
delivery, nerve regeneration, and tissue engineering.
If you would like to join our team, we would like hear from you.
Please contact info@tissuegen.com
EXECUTIVE MANAGEMENT
Kevin D. Nelson, PhD
Founder and Chief Scientific Officer
After completing his Ph.D. in 1995 in the field of biomedical engineering at The University of Texas Southwestern Medical Center in Dallas, Kevin joined the faculty at The University of Texas at Arlington where he earned tenure in 2003 and resigned in 2005 to become a full-time Founder and Chief Scientific Officer of TissueGen, Inc. He is an inventor on numerous patents that comprise the foundation of TissueGen's technology in the areas of drug protection and delivery. He continues to keep close to the university and currently serves as the head of the bioengineering industrial advisory board.
Sharon Bakalash, MD, PhD, CBA
Chief Executive Officer
Dr. Bakalash is a seasoned biotechnology entrepreneur and an ophthalmic surgeon with more than two decades of demonstrated leadership in Business, science, and medicine. Before stepping in as TissueGen’s CEO, she headed several biotechnology companies in the ophthalmic space (dSentz, OphRx) and is the founder of SB Strategic Development Consultants Group, which provides clinical development, strategic planning, and business development guidance, where she has been working closely with start-up companies, venture funds and global pharma companies- spanning the pharmaceutical, drug delivery and surgical device arenas.
​
Dr. Bakalash holds an MD from Ben Gurion University, a PhD in Neuroimmunology from the Weizmann Institute of Science, and a Business degree from Northeastern University. Dr. Bakalash has also completed a post-doctoral fellowship at Harvard University.
BOARD OF DIRECTORS
Kevin Cordell
Mr. Cordell currently serves as President, U.S. Extremities, for Wright Medical Technology, Inc. He received his Bachelor’s Degree in Finance from the University of Oklahoma.
James Dukowitz
Ph.D (Chairman)
Dr. Dukowitz has more than 35 years of experience in high-tech industries, with particular strengths in the areas of strategic planning, business development, communications, international marketing, and technology commercialization. He earned his Bachelor’s Degree in Mathematics from the University of Iowa and his Ph.D. in Political Science with an emphasis on Science, Technology, and Public Policy from the Massachusetts Institute of Technology.
Jonathan Gibson
Mr. Gibson is the Chief Executive Officer and General Partner at Socratic Fund Management L.P., the firm he founded in 1997. He has extensive experience in the investment and energy industry. He graduated from Lehigh University.
Charles Munson
Mr. Munson is Manager and President of NCC Nano, LLC dba NovaCentrix, and three additional companies involved in oil and gas production or minerals. He has over 25 years of experience in energy markets and technologies including photovoltaics and oil exploration and recovery. Mr. Munson graduated from Brown University with a dual degree in Geophysics and Math.
Dr. Kevin D. Nelson
Founder and CSO
Kevin Nelson, Founder and CSO, also serves on the Board of Directors.
Richard W. Snyder II
MD, FACC
Dr. Snyder is a cardiologist at Medical City Dallas Hospital and board-certified in Cardiovascular Disease, Interventional Cardiology, Advanced Heart Failure, and Transplant Cardiology. After graduating from the University of Notre Dame, he completed medical school at the University of Texas Southwestern Medical School, with a residency in internal medicine and fellowship in cardiovascular disease.
Scott Salka
Scott Salka is the Chief Executive Officer at MorphImmune and also serves as Executive Chair for Novosteo.
MEDICAL ADVISORY BOARD
Andreas M. Sauerbrey
MD
Dr. Sauerbrey is a board-certified, fellowship-trained orthopaedic surgeon specializing in shoulder/upper extremity surgery, sports medicine and joint restoration. He completed his medical degree in 1992 from Oregon Health Sciences University and orthopedic residency at the University of Colorado. He also completed a fellowship training in shoulder and elbow surgery at the University of Pennsylvania and a fellowship in hand surgery at Thomas Jefferson University in Philadelphia. He has been a team physician for the USSA (United States Ski and Snowboard Assoc.) and the US Ski Team since 2001.
Lisa A. Fortier
DVM, PHD, DACVS
Dr. Fortier is a Professor of Surgery at Cornell University in Ithaca, NY. She received her DVM from Colorado State University and completed her Ph.D. and surgical residency training at Cornell University. Her expertise is in Equine orthopedic surgery and research and her current laboratory projects include equine embryonic stem cells, the role of Rho-subfamily GTPases in cartilage homeostasis, tetracyclines as therapeutics for arthritis, platelet rich plasma for tendon and suspensory ligament regeneration.
Richard W. Snyder II
MD, FACC
Dr. Snyder serves on both the Board of Directors and the Medical Advisory Board at TissueGen.
TEAM
Dr. Brent Crow
Director, Special Programs
Brent joined TissueGen in 2006 as Senior Project Scientist/Engineer, and was named Director, Research and Development in 2012, followed by Director, Special Programs in 2016. He received a B.S. in Aeronautical Engineering from Embry-Riddle Aeronautical University, and was awarded a Ph.D. in Biomedical Engineering from the Joint Program at the University of Texas at Arlington/University of Texas Southwestern Medical Center. Brent began his career with Lockheed Martin, then served at Chair of the Biomedical Engineering Technology department at DeVry University before joining TissueGen.
Dr. Jennifer Seifert
Senior Director, Research and Development
Jennifer joined TissueGen as Senior Scientist in 2015, was named Director, Research and Development in 2016 and Senior Director in 2020. Jennifer received a B.S. in Biology from The University of Texas at Dallas followed by a Ph.D. in Molecular Biology from Texas Woman’s University in 2008. Postdoctoral work with Texas Scottish Rite Hospital for Children and The University of Texas at Arlington led to follow on research faculty positions at UTA, UTD, and UT Southwestern before joining the TissueGen team.
Dr. Ric Zarzycki
Director, Quality and Regulatory Affairs
Ric joined TissueGen in 2018 as Director, Quality and Regulatory Affairs to lead the Company’s ISO 13485:2016 certification and provide regulatory support as the Company advances commercial applications for ELUTE fiber and related technologies. Dr. Zarzycki served for 21 years in numerous pharmaceutical and medical device Quality, Regulatory Affairs, and R&D at the University of Sheffield, before continuing postdoctoral work in Supramolecular Chemistry at Columbia University and his follow-on appointment as Assistant Professor in the Chemistry Department at the The University of Texas at Dallas.
Dr. Paul Sood
Director, Product Development
Paul joined TissueGen in 2016 as Principal Scientist, and assumed the role of Director, Product Development in 2020. Paul obtained his B.Sc.(Hons.) degree in Chemistry from the University of Glasgow, Scotland and M.S. and Ph.D. degrees also in Chemistry from the University of Massachusetts at Amherst. In 1998 he joined Southern Methodist University in Dallas as a National Science Foundation Postdoctoral Fellow before entering industry as Senior Scientist at Access Pharmaceuticals Inc. in 2001, where he remained until 2012. He then joined ULURU Inc. where he served as Director, Project Management from 2012-2016 before joining TissueGen.
COMPLIANCE
ISO Class 7 Clean Room
TissueGen develops ELUTE fiber in an ISO Class 7 cleanroom environment to support compliance with drug and medical device cGMP regulations.
ISO Certification
As an ISO 13485:2016 certified facility, we adhere to quality management system requirements for medical devices. Our processes and controls are designed to ensure quality, safety and reliability.